A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and Navocaftor
Study Identifier
M23-492
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete
Study Details
Medical Condition
Study Drug
Phase
Phase 1
Sex
Female & Male
Age
18 - 65 Years
Protocol Summary
Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects the lungs and digestive system, significantly impairing the quality of life, with those affected having a median age of death at 40. The objectives of this study are to assess the effect of food on the safety and pharmacokinetics of navocaftor and galicaftor.
Study Locations
Location
Status
Location
Clinical Pharmacology of Miami /ID# 249531
Miami, Florida, United States, 33014
Status
Not applicable
Location
Acpru /Id# 249532
Grayslake, Illinois, United States, 60030
Status
Not applicable